Pyxis Oncology (PYXS) Preferred Stock Liabilities (2020 - 2021)
Pyxis Oncology (PYXS) reported Preferred Stock Liabilities of $21.9 million for Q3 2021, little changed year-over-year from $21.9 million in Q3 2020, and little changed on a QoQ basis from $21.9 million in Q2 2021.
Pyxis Oncology (PYXS) has 2 years of Preferred Stock Liabilities data on file, last reported at $21.9 million in Q3 2021.
- Quarterly Preferred Stock Liabilities changed 0.0% year-over-year to $21.9 million in Q3 2021, while the trailing twelve-month figure through Sep 2021 was $21.9 million (changed 0.0% YoY) and the FY2020 annual result came in at $21.9 million, changed N/A from the prior year.
- Preferred Stock Liabilities steadied at $21.9 million in Q3 2021 per PYXS's latest filing, from $21.9 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $172.1 million in Q1 2021 and bottomed at $21.9 million in Q3 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | - |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | - |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | - |
| 10 | Pyxis Oncology | 120.87 Mn | 103.97 Mn | 8.65 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 21.94 Mn |
| Jun 30, 2021 | 21.94 Mn |
| Mar 31, 2021 | 172.08 Mn |
| Dec 31, 2020 | 21.94 Mn |
| Sep 30, 2020 | 21.94 Mn |